Physician profile
Dennis Citrin
NPI 1518944800
$61,657.77
in general payments reported to CMS, 2019-2025
8 companies · $64.44 in 2025
The $64.44 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,838 · 2022: $18K · 2023: $19K · 2024: $18K · 2025: $64.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Travel and Lodging: $3,644 · Consulting Fee: $1,873 · Food and Beverage: $136 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,550.00 |
| Travel and Lodging | $3,643.58 |
| Consulting Fee | $1,872.50 |
| Food and Beverage | $135.58 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $58,990.28 | 2019-2024 | Lynparza, Enhertu |
| R-Pharm US LLC | $2,431.76 | 2019-2022 | |
| Gilead Sciences, INC. | $110.56 | 2023 | Trodelvy |
| Lilly USA, LLC | $41.85 | 2025 | Verzenio |
| Merck Sharp & Dohme LLC | $34.37 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.59 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.64 | 2019 | |
| Tactile Systems Technology INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Citrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.